Published in Ann Rheum Dis on August 17, 2005
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology (2011) 2.00
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis (2010) 1.78
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab (2015) 1.63
Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.48
Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford) (2014) 1.45
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol (2013) 1.40
Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskelet Disord (2016) 1.40
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 1.31
Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther (2008) 1.16
Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother (2013) 1.08
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther (2011) 1.04
Optimising corticosteroid treatment for autoimmune pancreatitis. Gut (2007) 1.01
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther (2009) 1.00
The Development of Novel Therapies for Rheumatoid Arthritis. Expert Opin Ther Pat (2008) 0.99
Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther (2008) 0.98
Acute effect of electroacupuncture at the Zusanli acupoints on decreasing insulin resistance as shown by lowering plasma free fatty acid levels in steroid-background male rats. BMC Complement Altern Med (2009) 0.94
Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. Arthritis Res Ther (2009) 0.93
Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology (2010) 0.90
The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther (2014) 0.87
Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers. J Am Soc Nephrol (2016) 0.86
Success with single-agent immunosuppression for multifocal choroidopathies. Am J Ophthalmol (2014) 0.86
Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. Ther Drug Monit (2014) 0.86
Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis. Rheumatol Int (2012) 0.85
Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol (2008) 0.84
Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care (2013) 0.83
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum (2013) 0.83
Treatment and relapse of autoimmune pancreatitis. Gut Liver (2008) 0.82
Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol (2015) 0.81
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open (2014) 0.81
Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols. BMC Neurol (2012) 0.80
Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD Open (2015) 0.79
Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Res Ther (2015) 0.78
The calcitonin and glucocorticoids combination: mechanistic insights into their class-effect synergy in experimental arthritis. PLoS One (2013) 0.78
Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol (2012) 0.78
Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. BMC Musculoskelet Disord (2016) 0.78
Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2012) 0.77
A dexamethasone prodrug reduces the renal macrophage response and provides enhanced resolution of established murine lupus nephritis. PLoS One (2013) 0.77
Glucocorticoids: complications to anticipate and prevent. Neurohospitalist (2013) 0.77
Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia. Clin Med Insights Circ Respir Pulm Med (2013) 0.77
Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats. Clin Interv Aging (2015) 0.76
Mathematical modeling of the circadian dynamics of the neuroendocrine-immune network in experimentally induced arthritis. Am J Physiol Endocrinol Metab (2016) 0.76
Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol (2013) 0.76
One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. RMD Open (2016) 0.75
Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? Arthritis Res Ther (2009) 0.75
The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther (2016) 0.75
Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes. Front Immunol (2016) 0.75
Steroid withdrawal after renal transplantation: a retrospective cohort study. BMC Med (2017) 0.75
Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One (2014) 0.75
Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 /μL. PLoS One (2015) 0.75
Osteoporosis in adult patients with atopic dermatitis: A nationwide population-based study. PLoS One (2017) 0.75
Outcome Preferences in Patients With Noninfectious Uveitis: Results of a Best-Worst Scaling Study. Invest Ophthalmol Vis Sci (2015) 0.75
[EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases]. Z Rheumatol (2009) 0.75
An evaluation of the effect of pulsed wave low-level laser therapy on the biomechanical properties of the vertebral body in two experimental osteoporosis rat models. Lasers Med Sci (2015) 0.75
The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study. Clin Rheumatol (2013) 0.75
Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Ophthalmology (2017) 0.75
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis. Arthritis Care Res (Hoboken) (2016) 0.75
Does corticosteroid treatment cause prolonged recovery and increased total bilirubin level in severe ADAMTS-13-deficient TTP patient? Wien Klin Wochenschr (2015) 0.75
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65
Identification of a gene that causes primary open angle glaucoma. Science (1997) 8.14
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med (1995) 6.14
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med (1995) 5.83
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med (1976) 3.19
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med (2002) 3.10
Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med (1983) 3.04
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med (1994) 2.89
Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med (1991) 2.77
Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med (1997) 2.73
Changes in visual acuity in a population over a 10-year period : The Beaver Dam Eye Study. Ophthalmology (2001) 2.71
Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc (1996) 2.65
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum (2001) 2.59
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis (1990) 2.42
Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med (1992) 2.39
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med (2004) 2.39
Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids. N Engl J Med (1957) 2.38
Statins and the acute-phase response. N Engl J Med (2001) 2.28
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.27
Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum (1999) 2.21
Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest (1997) 2.21
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum (2000) 2.06
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol (1996) 1.86
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med (1993) 1.80
Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med (1974) 1.80
Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) (1983) 1.79
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis (2004) 1.69
Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) (1987) 1.67
Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord (1983) 1.65
Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol (1998) 1.65
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest (1997) 1.63
Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med (2000) 1.62
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol (1998) 1.61
Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther (1989) 1.46
Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med (1985) 1.45
Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol (1983) 1.43
Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax (1968) 1.43
Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med (1994) 1.41
Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol (2000) 1.39
Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol (1994) 1.37
The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med (2000) 1.31
Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med (1972) 1.27
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology (2001) 1.24
Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf (2000) 1.24
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab (2001) 1.23
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res (2000) 1.23
Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab (2001) 1.19
Corticosteroids and infectious diseases. Med Clin North Am (1973) 1.17
Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) (1992) 1.15
Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology (1996) 1.13
Corticosteroids and glaucoma risk. Drugs Aging (1999) 1.13
Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol (1997) 1.13
Acute suppression of circulating testosterone levels by cortisol in men. J Clin Endocrinol Metab (1983) 1.11
The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum (1991) 1.09
Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med (1986) 1.06
Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol (1979) 1.06
Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am (1999) 1.04
The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol (2000) 1.03
Changes in cortisol metabolism following rifampicin therapy. Lancet (1974) 1.02
Effect of corticosteroids on blood salicylate concentration. JAMA (1965) 1.01
Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J (1973) 1.01
Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum (1981) 1.00
Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab (1984) 1.00
Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism (1996) 1.00
Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb (1993) 0.99
Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens (1987) 0.98
Relationship between systemic corticosteroids and osteonecrosis. Am J Clin Dermatol (2001) 0.98
Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med (1990) 0.98
Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol (1992) 0.97
Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab (1983) 0.97
Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) (2001) 0.96
Anticonvulsant therapy and cortisol elimination. Br J Clin Pharmacol (1985) 0.96
Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J (1989) 0.96
Sudden death following high-dose intravenous methylprednisolone. Transplantation (1983) 0.94
Mineralo- and glucocorticoid effects on renal excretion of electrolytes. Pflugers Arch (1983) 0.94
Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med (1987) 0.94
Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med (1979) 0.93
Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther (1991) 0.92
Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med (1988) 0.92
Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am J Physiol (1975) 0.91
Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol (2001) 0.90
Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol. Am J Physiol (1997) 0.90
The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens (1989) 0.90
Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol (1994) 0.90
Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol (2000) 0.89
Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) (2002) 0.89
The effect of dexamethasone on renal electrolyte excretion in the adrenalectomized rat. Endocrinology (1982) 0.89
Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med (1983) 0.88
Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol (1995) 0.88
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol (1998) 7.43
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med (1995) 5.83
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis (2007) 3.89
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis (2005) 3.53
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Making original data from clinical studies available for alternative analysis. J Rheumatol (1997) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Urgency and priority for cardiac surgery: a clinical judgment analysis. BMJ (1998) 2.90
Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. Ann Rheum Dis (1983) 2.83
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
Radiographic assessment of the knee joint in osteoarthritis. Ann Rheum Dis (1992) 2.75
OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol (1993) 2.74
[Polymyalgia rheumatica and temporal arteritis]. Ned Tijdschr Geneeskd (2005) 2.68
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol (1999) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Clinical judgment in rheumatoid arthritis. II. Judging 'current disease activity' in clinical practice. Ann Rheum Dis (1983) 2.44
Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum (2000) 2.29
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
Signaling takes a breath--new quantitative perspectives on bioenergetics and signal transduction. Immunity (2001) 2.26
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1996) 2.08
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. Ann Rheum Dis (1986) 2.06
Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis (2011) 2.04
Infectious diarrhea secondary to Enteromonas hominis. Am J Gastroenterol (1989) 2.03
Judging "current disease activity" in rheumatoid arthritis--an international comparison. J Rheumatol (1983) 2.01
Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol (2008) 1.99
Quality of life measures. Br J Rheumatol (1996) 1.97
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet (1983) 1.94
Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev (2007) 1.91
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia (2009) 1.87
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology (2001) 1.85
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) (2005) 1.85
Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum (2004) 1.83
[Therapy of ankylosing spondylitis (AS) with radium chloride (224SpondylAT)]. Z Rheumatol (2001) 1.82
Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) (2002) 1.82
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis (2007) 1.73
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology (Oxford) (2005) 1.73
Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. Ann Rheum Dis (2008) 1.73
Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis (2009) 1.72
The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol (2001) 1.69
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol (2001) 1.64
Smallest detectable difference in radiological progression. J Rheumatol (1999) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol (1998) 1.61
Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol (1995) 1.61
Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol (2003) 1.60
Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum (1987) 1.60
Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci (1987) 1.60
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia (2013) 1.59
Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis (2005) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford) (1999) 1.57
Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol (1992) 1.56
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int (2006) 1.55
Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med (2010) 1.54
Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum (2007) 1.53
Clinical judgement analysis--practical application in rheumatoid arthritis. Br J Rheumatol (1983) 1.52
Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis (2000) 1.52
Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis. J Rheumatol (2000) 1.51
Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis (2008) 1.50
Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ Study. Ann Rheum Dis (2011) 1.50
Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.50
HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol (2000) 1.49
Do we need randomised trials to evaluate diagnostic procedures? For. Eur J Nucl Med Mol Imaging (2003) 1.48